

**General Information**

Name of the Company*	Samrat Pharmachem Limited
NSE Symbol*	NOTLISTED
BSE Scrip Code*	530125
MSEI Symbol*	NOTLISTED
ISIN*	INE103E01016
Type of Announcement*	New
Type of Event*	Issue of duplicate share certificates/Letter of Confirmation
Details of other event	
Date of original announcement	
Remarks (website dissemination)	
Remarks for Exchange (not for Website Dissemination)	
Date of Report	20-11-2025

Issue of Duplicate Share Certificates/Letter of Confirmation											
Number of shareholders to whom duplicate share certificate/Letter of Confirmation has been issued*								4			
Details of Shareholders to whom duplicate share certificate/Letter of Confirmation has been issued											
Date of receipt of information for issue of duplicate share certificate/Letter of Confirmation*	Name*	Folio Number	Number of Shares	Old Certificate Number		New Certificate/Letter of Confirmation Number		Distinctive Number		Reason for issue of duplicate share certificate/Letter of Confirmation	Non-Compliance trigger
				From	To	From	To	From	To		
19-11-2025	NAYNABEN C BHAGAT	10522	500	10524	10528	31004	31004	1052301	1052800	Original Lost	
19-11-2025	CHITRABEN H BHAGAT	12756	300	17860	17862	31005	31005	1785901	1786200	Original Lost	
19-11-2025	HEMANTKUMAR C BHAGAT	10317	500	9812	9816	31006	31006	981101	981600	Original Lost	
19-11-2025	PADMABEN C BHAGAT	12757	500	17863	17867	31007	31007	1786201	1786700	Original Lost	
Name of Registrar and Transfer Agent (RTA) of the Company*							Others				
Name of other RTA							MUFG Intime India Private Limited				
Whether the Company has complied with Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*							Yes				
If No, specify the reason											
Any other disclosure w.r.t. compliance of any SEBI Act, Regulation, Circular or provision											
Any other information											
Remarks (website dissemination)											
Remarks for Exchange (not for Website dissemination)											

**SAMRAT PHARMACHEM LIMITED**  
REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION  
FROM : TN54 TO :- TN57

Tr.no /Appr.Dt	FOLIO NO. SHAREHOLDER'S NAME	CERT.NO		DIST.NOS		SHARES	PAID VALUE	STUS	Deno	Cert Type	MICR From	MICR To
		FROM	TO	FROM	TO							
TN54 19/11/2025	0010522 NAYNABEN C BHAGAT HEMANT C BHAGAT	10524	10528	1052301	1052800	500 OLD ----- 500	10	DUP	500			
		31004	31004	1052301	1052800	500 NEW ----- 500	10		500			
TN55 19/11/2025	0012756 CHITRABEN H BHAGAT HEMANT C BHAGAT	17860	17862	1785901	1786200	300 OLD ----- 300	10	DUP	300			
		31005	31005	1785901	1786200	300 NEW ----- 300	10		300			
TN56 19/11/2025	0010317 HEMANTKUMAR C BHAGAT CHITRABEN H BHAGAT	9812	9816	981101	981600	500 OLD ----- 500	10	DUP	500			
		31006	31006	981101	981600	500 NEW ----- 500	10		500			
TN57 19/11/2025	0012757 PADMABEN C BHAGAT HEMANT C BHAGAT	17863	17867	1786201	1786700	500 OLD ----- 500	10	DUP	500			
		31007	31007	1786201	1786700	500 NEW ----- 500	10		500			

# SAMRAT PHARMACHEM LIMITED

REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION

FROM : TN54 TO :- TN57

\*\*\*\*\* BATCH CONTROLS\*\*\*\*\*

- |                                 |   |    |
|---------------------------------|---|----|
| 1. TOTAL NO.OF REQUESTS         | : | 4  |
| 2. TOTAL NO.OF OLD CERTIFICATES | : | 18 |
| 3. TOTAL NO.OF NEW CERTIFICATES | : | 4  |
| 4. TOTAL NO.OF PAGES            | : | 2  |

\*\*\*\*\* CERTIFICATE (S)CONTROLS\*\*\*\*\*

- |   |   |      |
|---|---|------|
| 5. TOTAL NO.OF DUPLICATED CERTIFICATE   | : | 4    |
| 6. TOTAL NO.OF DUPLICATED SHARES        | : | 1800 |
| 7. TOTAL NO.OF SUB DIVIDED CERTIFICATE  | : | 0    |
| 8. TOTAL NO.OF SUB DIVIDED SHARES       | : | 0    |
| 9. TOTAL NO.OF CONSOLIDATED CERTIFICATE | : | 0    |
| 10. TOTAL NO.OF CONSOLIDATED SHARES     | : | 0    |

## Samrat Pharmachem Limited

---

**From:** Alex Kundukulangara <alex.kundukulangara@in.mpms.mufig.com>  
**Sent:** 19 November 2025 14:09  
**To:** Samrat Pharmachem Limited  
**Cc:** Dilip Rajpurohit; 'Aqueel Mulla'  
**Subject:** RE: Approval Date - Samrat Pharmachem Limited  
**Attachments:** TN54-TN57 DUPLICATE REGISTER.pdf

Dear Ma'am,

Please find attached duplicate register for your record purposes.  
Request you to kindly scan and share duly signed copy of the register along with seal of authorized signatory before dispatching the same.

Thanks and Regards

Alex Kundukulangara  
Associate – Client Relations



### MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services  
(Formerly Link Intime India Private Limited)

C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083.

[www.in.mpms.mufig.com](http://www.in.mpms.mufig.com) | Follow us: [LinkedIn](#)

T: +91 22 4918 6000 M: +91 9619790927 (Ext: 2326)

[alex.kundukulangara@in.mpms.mufig.com](mailto:alex.kundukulangara@in.mpms.mufig.com)



Do you really need to print this email?

---

**From:** Samrat Pharmachem Limited <contact@samratpharmachem.in>  
**Sent:** 18 November 2025 15:50  
**To:** Alex Kundukulangara <alex.kundukulangara@in.mpms.mufig.com>  
**Cc:** Dilip Rajpurohit <dilip.rajpurohit@in.mpms.mufig.com>; 'Aqueel Mulla' <aqueelmulla@gmail.com>; contact@samratpharmachem.in  
**Subject:** RE: Approval Date - Samrat Pharmachem Limited

**CAUTION :** This email is received from an external domain. Open the hyperlink(s) & attachment(s) with caution.

Approval Date: 19/11/2025

Best Regards,

**Sheetal**  
**Samrat Pharmachem Limited**

**From:** Alex Kundukulangara [<mailto:alex.kundukulangara@in.mpms.mufig.com>]

**Sent:** 17 November 2025 10:47

**To:** Samrat Pharmachem Limited <[contact@samratpharmachem.in](mailto:contact@samratpharmachem.in)>

**Cc:** 'Rajesh Mehta' <[rajesh@samratpharmachem.com](mailto:rajesh@samratpharmachem.com)>; Dilip Rajpurohit <[dilip.rajpurohit@in.mpms.mufig.com](mailto:dilip.rajpurohit@in.mpms.mufig.com)>

**Subject:** Approval Date - Samrat Pharmachem Limited

Dear Sir/Ma'am,

We have received duplicate request(s) for 4 shareholders.

Inward Certificate No.	Inward Certificate Date	Seller Folio	Seller Name	Buyer Folio No	Buyer Name
DU1321	27/10/2025	0010522	NAYNABEN C BHAGAT	0010522	
DU1322	31/10/2025	0012756	CHITRABEN H BHAGAT	0012756	
DU1323	31/10/2025	0010317	HEMANTKUMAR C BHAGAT	0010317	
DU1324	27/10/2025	0012757	PADMABEN C BHAGAT	0012757	

Kindly provide approval date for our further course of action.

Thanks and Regards

Alex Kundukulangara  
Associate – Client Relations



**MUFG Intime India Private Limited**

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services  
(Formerly Link Intime India Private Limited)

C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083.

[www.in.mpms.mufig.com](http://www.in.mpms.mufig.com) | Follow us: [LinkedIn](#)

T: +91 22 4918 6000 M: +91 9619790927 (Ext: 2326)

[alex.kundukulangara@in.mpms.mufig.com](mailto:alex.kundukulangara@in.mpms.mufig.com)



DISCLAIMER: This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.

DISCLAIMER: This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.